Gastroesophageal symptoms significantly impact methotrexate dosages and disease activity among patients with RA.

TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...